pone.0294847.s002.docx (16.41 kB)
Inclusion and Exclusion criteria for the clinical trial.
journal contribution
posted on 2024-01-25, 18:40 authored by Ian R. Woodcock, George Tachas, Nuket Desem, Peter J. Houweling, Michael Kean, Jaiman Emmanuel, Rachel Kennedy, Kate Carroll, Katy de Valle, Justine Adams, Shireen R. Lamandé, Chantal Coles, Chrystal Tiong, Matthew Burton, Daniella Villano, Peter Button, Jean-Yves Hogrel, Sarah Catling-Seyffer, Monique M. Ryan, Martin B. Delatycki, Eppie M. YiuInclusion and Exclusion criteria for the clinical trial.
History
Usage metrics
Categories
Keywords
upper limb testupper limb functionstatistically significantly higherstatistically significant changeserious adverse eventssecondary objectives includednovel antisense drugmri fat fractionexacerbating muscle damagecontraction induced injuryapparent stabilisation observedphase 2 open2 &# 8217injection site erythemafunctional muscle strengthfour weeks past25 mg weeklyhigh cd49d expressingcd49d alpha subunitstudy duration supportmean change 0week 28 comparedxlink "> atl1102xlink ">pul 2weekly dosingsubcutaneous injectionmyopinch comparedfunctional changesweek 824 weekswell toleratedweek 24stable throughoutstable doseskin discolorationreducing survivalprogressive weakesspinch measurespharmacokinetic profileparticipant withdrawalsnine participantsmyoset gripmain objectivelymphocyte numberslymphocyte countlast doselabel studyinhibiting expressionincreased numbersimmune systemforearm musclesdosing howeverdisease severitycontinued developmentci 0cells correlatingatl1102 administeredambulatory boysambulant boys18 years030 ).
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC